Want to see AIFF full AI Analyst Report?
Top Page
Firefly Neuroscience
(NASDAQ:AIFF)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▼(-9.91% Downside)
Action:Reiterated
Date:08/08/26
The score is held down primarily by very weak profitability and significant cash burn despite strong revenue growth and healthy gross margins. Technical signals are neutral-to-soft with the stock below key longer-term moving averages, and valuation is constrained by losses (negative P/E) with no dividend support. Corporate events are mixed, with financing uncertainty partially offset by capital structure and leadership adjustments.
Positive Factors
Revenue growth & gross margin
Sustained TTM revenue growth (~+38.7%) combined with ~52% gross margin implies the product can scale with attractive unit economics. Over the next 2–6 months this supports reinvestment in R&D and commercialization while giving a clearer path to operating leverage if fixed costs are controlled.
Negative Factors
High operating cash burn
Persistent negative operating and free cash flow (~-$7.6M / -$7.8M TTM) shows the business is converting losses into real cash outflows. Over the next several months this creates runway pressure and forces reliance on external financing unless operational cash generation improves materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & gross margin
Sustained TTM revenue growth (~+38.7%) combined with ~52% gross margin implies the product can scale with attractive unit economics. Over the next 2–6 months this supports reinvestment in R&D and commercialization while giving a clearer path to operating leverage if fixed costs are controlled.
Read all positive factors
Firefly Neuroscience (AIFF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.20M
Dividend YieldN/A
Average Volume (3M)316.76K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth320.33%
EPS Growth79.09%
CountryUS
Employees17
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.64
Shares Outstanding15,690,316
10 Day Avg. Volume358,037
30 Day Avg. Volume316,761
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.51
Price to Sales (P/S)10.11
P/FCF Ratio-1.39
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue10.73
Enterprise Value/Gross Profit24.06
Enterprise Value/Ebitda-2.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Firefly Neuroscience Business Overview & Revenue Model
Company Description
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected ...
How the Company Makes Money
null...
Firefly Neuroscience Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.80M | 1.14M | 108.00K | 498.00K | 0.00 | 32.00K |
| Gross Profit | 802.00K | 645.00K | 41.00K | 498.00K | 0.00 | 32.00K |
| EBITDA | -8.87M | -19.55M | -10.32M | -2.58M | -3.20M | -3.82M |
| Net Income | -9.11M | -19.88M | -10.46M | -2.60M | -3.79M | -4.38M |
Balance Sheet | ||||||
| Total Assets | 16.77M | 10.48M | 4.60M | 2.64M | 135.00K | 953.00K |
| Cash, Cash Equivalents and Short-Term Investments | 9.23M | 2.75M | 1.81M | 2.14M | 58.00K | 653.00K |
| Total Debt | 0.00 | 0.00 | 694.00K | 0.00 | 0.00 | 1.79M |
| Total Liabilities | 2.10M | 2.84M | 4.98M | 2.53M | 2.25M | 3.97M |
| Stockholders Equity | 14.66M | 7.64M | -375.00K | 109.00K | -2.11M | -3.01M |
Cash Flow | ||||||
| Free Cash Flow | -7.20M | -8.32M | -6.57M | -2.56M | -2.89M | -3.82M |
| Operating Cash Flow | -6.99M | -8.19M | -6.16M | -2.17M | -2.89M | -3.82M |
| Investing Cash Flow | -209.00K | -2.49M | -477.00K | -386.00K | 262.00K | 1.60M |
| Financing Cash Flow | 10.51M | 11.62M | 6.30M | 4.64M | 2.04M | 2.04M |
Firefly Neuroscience Technical Analysis
Negative
1.11
Price Trends
1.26
Negative
1.58
Negative
1.45
Negative
Market Momentum
-0.03
Negative
42.92
Neutral
37.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIFF, the sentiment is Negative. The current price of 1.11 is below the 20-day moving average (MA) of 1.13, below the 50-day MA of 1.26, and below the 200-day MA of 1.45, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.92 is Neutral, neither overbought nor oversold. The STOCH value of 37.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIFF.
Firefly Neuroscience Risk Analysis
Firefly Neuroscience disclosed 73 risk factors in its most recent earnings report. Firefly Neuroscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Firefly Neuroscience Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $4.06B | -294.05 | -8.97% | ― | 25.58% | 85.38% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
48 Neutral | $98.90M | -5.26 | -50.17% | ― | ― | 70.27% | |
46 Neutral | $18.20M | -1.71 | -229.99% | ― | 320.33% | 79.09% | |
45 Neutral | $15.93M | -2.12 | -98.33% | ― | -1.67% | 7.34% |
* Technology Sector Average
AIFF
Firefly Neuroscience
1.09
-1.66
-60.36%
IRTC
Irhythm Technologies
126.44
-34.14
-21.26%
NMTC
NeuroOne Medical Technologies
1.94
-2.98
-60.55%
CGTX
Cognition Therapeutics
1.01
-0.53
-34.42%
Firefly Neuroscience Corporate Events
Business Operations and StrategyShareholder Meetings
Firefly Neuroscience Expands Incentive Plan, Tightens Capital Structure
Positive
Aug 7, 2026
On August 5, 2026, Firefly Neuroscience stockholders approved an amendment to the 2024 Long-Term Incentive Plan, adding 2,000,000 shares to the pool available for equity awards and updating the plan’s evergreen share replenishment feature. T...
Business Operations and StrategyPrivate Placements and Financing
Firefly Neuroscience Ends Financing Agreement, Explores New Options
Negative
Jun 26, 2026
Firefly Neuroscience, Inc. had previously entered into a securities purchase agreement with an accredited investor on May 6, 2026, to sell up to 666,667 units at $1.50 per unit, targeting gross proceeds of up to $1 million. On June 25, 2026, the c...
Business Operations and StrategyExecutive/Board Changes
Firefly Neuroscience Reassigns Former CTO to AI Leadership
Positive
Jun 22, 2026
On June 18, 2026, Deel Innovation Ltd., a consulting provider to Firefly Neuroscience, entered into an employment agreement with former Chief Technology Officer Gil Issachar, under which he now serves as Head of AI and Neuroscience at Firefly. The...
Private Placements and FinancingRegulatory Filings and Compliance
Firefly Neuroscience Announces Private Placement Equity Financing
Neutral
May 12, 2026
On May 6, 2026, Firefly Neuroscience entered into a securities purchase agreement with an accredited investor to sell up to 666,667 units at $1.50 per unit, for potential gross proceeds of up to $1 million. Each unit comprises one share of common ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.